Stereotactic ablative radiotherapy (SABR), or stereotactic body radiotherapy (SBRT), has recently been applied in the field of arrhythmia management. It has been most widely assessed in the treatment of ventricular tachycardia (VT) but may also have potential in the treatment of other arrhythmias as well, often termed stereotactic arrhythmia radiotherapy (STAR). The non-invasive delivery of treatment for VT has the potential to spare an often physiologically vulnerable group of patients the burden of long catheter ablation procedures with the potential for prolonged periods of hemodynamic instability. Cardiac SABR also has the capacity to direct ablative therapy at substrate that is inaccessible using current transchatheter techniques. For these reasons cardiac SABR has generated significant enthusiasm as an emerging treatment modality for VT. We consider in review the pre-clinical data pertaining to the use of SABR in cardiac tissue and recent clinical evidence regarding the application of SABR in the field of arrhythmia management.

立体定向消融放射治疗 (SABR) 或立体定向身体放射治疗 (SBRT) 最近已应用于心律失常管理领域。它已在室性心动过速 (VT) 的治疗中得到最广泛的评估，但也可能在其他心律失常的治疗中具有潜力，通常称为立体定向心律失常放疗 (STAR)。VT 的无创治疗有可能使生理上易受伤害的患者群体免于长期导管消融手术的负担，这些手术可能会导致长时间的血流动力学不稳定。心脏 SABR 还具有在使用当前经导管技术无法接近的基质上指导消融治疗的能力。由于这些原因，心脏 SABR 作为一种新兴的 VT 治疗方式引起了极大的热情。关于在心脏组织中使用 SABR的临床前数据以及关于在心律失常管理领域中应用 SABR 的最新临床证据。